Regeneron Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REGN research report →
Companywww.regeneron.com
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- CEO
- Leonard S. Schleifer
- IPO
- 1991
- Employees
- 15,158
- HQ
- Tarrytown, NY, US
Price Chart
Valuation
- Market Cap
- $66.94B
- P/E
- 15.28
- P/S
- 4.49
- P/B
- 2.15
- EV/EBITDA
- 11.61
- Div Yield
- 0.56%
Profitability
- Gross Margin
- 84.55%
- Op Margin
- 24.32%
- Net Margin
- 29.65%
- ROE
- 14.32%
- ROIC
- 8.53%
Growth & Income
- Revenue
- $14.34B · 0.99%
- Net Income
- $4.50B · 2.09%
- EPS
- $43.07 · 5.31%
- Op Income
- $3.58B
- FCF YoY
- 11.35%
Performance & Tape
- 52W High
- $821.11
- 52W Low
- $476.49
- 50D MA
- $736.73
- 200D MA
- $692.18
- Beta
- 0.30
- Avg Volume
- 739.72K
Get TickerSpark's AI analysis on REGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | RYAN ARTHUR F | sell | 5 |
| May 1, 26 | RYAN ARTHUR F | sell | 15 |
| May 1, 26 | RYAN ARTHUR F | sell | 24 |
| May 1, 26 | RYAN ARTHUR F | sell | 15 |
| May 1, 26 | RYAN ARTHUR F | sell | 14 |
| May 1, 26 | RYAN ARTHUR F | sell | 7 |
| May 1, 26 | RYAN ARTHUR F | sell | 4 |
| May 1, 26 | RYAN ARTHUR F | sell | 6 |
| May 1, 26 | RYAN ARTHUR F | sell | 2 |
| May 1, 26 | RYAN ARTHUR F | sell | 5 |
Our REGN Coverage
View all →
Regeneron Pharmaceuticals, Inc. (REGN) falls 11.9% on trial miss
Regeneron Pharmaceuticals, Inc. (REGN) falls sharply after hours after a late-stage melanoma study for fianlimab missed its primary endpoint. The selloff was amplified by analyst downgrades and renewed concern over Eylea erosion risk, even as the company remains highly profitable with strong recent earnings.
Regeneron Pharmaceuticals (REGN): Dupixent Growth Offsets EYLEA Pressure
Regeneron combines a durable cash engine with a broad pipeline, while Dupixent growth and EYLEA HD adoption help offset legacy EYLEA biosimilar pressure. The stock screens as a Buy with valuation still reasonable for a mature biotech compounder.
Regeneron Pharmaceuticals, Inc. (REGN) drops on EYLEA pressure
Regeneron Pharmaceuticals, Inc. (REGN) drops after its latest earnings report despite beating estimates on both profit and revenue. Investors focused instead on weakening EYLEA sales, lower gross margin guidance, and signs that the company’s core eye-drug franchise is under pressure.
Want a deeper read on REGN?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.